The Investigative Journal reviewed SEC press releases, EDGAR filings and public enforcement records posted through October 20, 2026. Unless otherwise noted, statements below reflect what the cited documents say; they are not findings by TIJ. Where a filing summary came from a third-party aggregator, we say so and link the original EDGAR document when available.
1. Salesforce Agrees to Acquire Braze for $47.50 Per Share (Form 8-K)
The largest deal in this morning’s docket is Salesforce’s agreement to acquire marketing-automation company Braze, Inc. According to a Form 8-K filed October 20, 2026 and summarized by StockTitan, Salesforce will pay $47.50 per share in cash through a merger subsidiary, valuing the transaction at roughly $5.66 billion in enterprise value. The Braze board approved the agreement unanimously, and closing requires approval from a majority of outstanding Class A shares, expiration of the Hart-Scott-Rodino waiting period and other specified antitrust and foreign-investment clearances.
The termination provisions deserve attention. The filing indicates Salesforce would owe Braze $300 million in specified circumstances, such as a legal prohibition or the outside date passing, while Braze would owe Salesforce about $191.4 million if, for example, its board changes its recommendation or accepts a superior proposal. A reverse fee that large generally signals that the buyer expects, or the target wants protection against, regulatory scrutiny. The agreement also references a “Burdensome Condition” standard, which governs how far Salesforce must go to win approvals. Shareholders will want to read the proxy statement the companies must file, which should lay out the background of the sale process and any competing interest.
The original EDGAR document should be consulted for the authoritative text; the aggregator page we reviewed did not provide a direct EDGAR link. Braze and Salesforce have not, to our knowledge, been accused of any wrongdoing; this is an ordinary-course merger disclosure.
2. Merck KGaA to Acquire Silence Therapeutics for About $1.3 Billion (Form 8-K)
Silence Therapeutics plc disclosed in an 8-K filed October 19, 2026 that it agreed to be acquired by Merck KGaA of Darmstadt, Germany, for $20.00 in cash per American depositary share. Per the filing, that represents a 130 percent premium to the October 16 closing price and 82 percent over the 30-day volume-weighted average of $10.99. The transaction values Silence’s equity at about $1.3 billion, with enterprise value near $1.1 billion, and is structured as a U.K. scheme of arrangement requiring a 75 percent-in-value shareholder vote and High Court sanction.
Holders of roughly 14 percent of voting power have signed support agreements, and the deal carries no financing condition. The filing lists an expected close in the first quarter of 2027, an outside date of April 30, 2027, and a $13 million break fee payable by Silence in specified circumstances. A premium of this size for a clinical-stage company is a reminder of how much value can ride on a single pipeline. Investors should read the risk-factor and scheme-document disclosures closely, since the premium also implies the market had priced the shares well below what the buyer ultimately judged them to be worth.
3. Expand Energy Names Daniel Brown CEO, Discloses Large Make-Whole Awards (Form 8-K)
Expand Energy Corp. filed an 8-K on October 19, 2026 announcing that Daniel E. Brown, formerly CEO of Chord Energy, will become president and CEO, with employment expected to begin October 26. He succeeds Michael Wichterich, who has served as interim CEO since February 2026 and will remain board chairman. The company states the transition was planned and not the result of a disagreement.
The compensation terms are the notable element. According to the offer-letter summary in the filing, Brown receives a $1 million base salary, a 125 percent target bonus, and annual long-term incentives with a $8.75 million target value. He also receives make-whole awards intended to replace forfeited pay at his prior employer: restricted stock units with a $4.73 million target value and performance units with a $10.93 million target value. Those performance units vest on total shareholder return over periods ending 2028 through 2030 and accelerate on a qualifying termination. Make-whole awards are common in executive recruitment, but their size is a fair subject for shareholders when the company next files its proxy statement and say-on-pay proposal. Wichterich, per the filing, receives a pro-rata 2026 award and no other transition payments.
4. Centrus Energy Completes $116 Million Westerman Acquisition (Form 8-K)
Centrus Energy Corp. reported in an 8-K covering an October 16, 2026 closing that it bought Westerman Holdings, LLC from the Westerman Employee Stock Ownership Trust for about $116 million, paid as $95 million in cash and $21 million in Class A common stock. The filing indicates roughly $31.5 million went to retire Westerman’s subordinated notes and $12.7 million to repay a term loan.
Because part of the consideration is stock issued under a private-placement exemption, Centrus agreed to use reasonable best efforts to register those shares for resale. Investors in a company tied to the nuclear fuel supply chain should watch for that registration statement, as resale of the shares could add supply to the market. The price is also subject to a working-capital adjustment, so the final figure may differ.
5. SEC Seeks Final Judgment Against Former Western Asset Co-CIO Ken Leech (Enforcement)
In Press Release 2026-103 (October 6, 2026), the SEC announced that Ken Leech, the former co-chief investment officer of Western Asset Management, consented, without admitting or denying the allegations, to a proposed final judgment that would impose a $3 million penalty, an officer-and-director bar and a permanent antifraud injunction. The judgment remains subject to court approval, and he also agreed to an associational bar.
The SEC’s November 2024 complaint alleged that from at least January 2021 through October 2023 Leech engaged in cherry-picking, delaying trade allocations until after futures settlement prices were known so that gains went to favored portfolios and losses to others. The agency says the alleged first-day gains and losses amounted to hundreds of millions of dollars. The release states that Western Asset separately agreed in June 2026 to a $100 million civil penalty and a Fair Fund, and that the SEC says the two resolutions will return $103 million to harmed investors. The release also notes Leech pleaded guilty in June 2026 in the Southern District of New York to obstruction of justice tied to testimony he gave the SEC. That is a distinct charge from the cherry-picking allegations, which he has not admitted in the civil settlement.
6. Dada Nexus Settles Revenue-Overstatement Charges
A September enforcement roundup from Morgan Lewis reports that on September 11 the SEC instituted settled proceedings against China-based Dada Nexus Limited over sham advertising and marketing transactions that allegedly overstated net revenue by about $80 million and costs by about $81 million. The company agreed to a cease-and-desist order and a $500,000 penalty; the Commission reportedly cited the company’s cooperation in setting the amount. The SEC order is public. The matter is a reminder that revenue-quality questions for foreign issuers listed in the United States remain an enforcement focus, and that cooperation credit can sharply reduce penalties.
The same roundup describes other September settlements, including a $575,000 Regulation SCI penalty against OTC Link LLC and a $450,000 penalty against Zoe Financial, Inc. over undisclosed conflicts. Each was a settled order; none involved a trial finding.
7. Commission Down to Two Members as Quorum Rule Changes
Per the National Law Review’s October regulatory update, Commissioner Hester Peirce’s departure took effect October 2, leaving Chairman Paul Atkins and Commissioner Mark Uyeda. The same update reports the Commission amended its Rule 200.41, effective October 2 and adopted without notice and comment, so that a single commissioner can form a quorum if the others are disqualified from a matter. Those facts matter for enforcement timing, since settled actions and rulemakings require Commission votes. Enforcement Director David Woodcock has described a “back to basics” approach centered on individual accountability and returning money to investors, and said staff will monitor Form 8-K filings and media reports, according to Morgan Lewis.
8. Proxy Rule Proposal Would Rescind Rule 14a-8
For readers who follow proxy statements, the SEC’s September 16 proposal would rescind Rule 14a-8, the shareholder-proposal rule, and update proxy solicitation rules, with comments due November 20, 2026, according to the National Law Review. If adopted, it would change what appears in DEF 14A filings next spring. Separately, third-quarter Form 13F filings reporting institutional holdings are due 45 days after quarter end, which falls on November 14, so the next major ownership-change data set is not yet available.
Filings That May Warrant Deeper TIJ Review
Several items merit follow-up. First, the Braze proxy statement, once filed, should reveal the sale process and any other bidders. Second, Expand Energy’s next proxy statement will show how shareholders respond to a make-whole package totaling more than $15 million in target value. Third, the Silence scheme document will disclose the fairness analysis behind a 130 percent premium. Fourth, the Western Asset Fair Fund distribution plan will show how and when harmed investors are paid. Finally, any court order approving the Leech consent judgment should be checked against the SEC’s description. TIJ has not contacted the companies or individuals named here for comment ahead of this digest; each is welcome to submit a response, and we will note it. Nothing here is a finding of wrongdoing beyond what the cited public documents state, and pending matters remain allegations or proposed settlements unless a court or the Commission has ruled.
Sources: SEC press releases; SEC Release 2026-103; Silence Therapeutics 8-K; Expand Energy 8-K; Centrus Energy 8-K; Braze 8-K summary (StockTitan); Morgan Lewis; National Law Review.